<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902432</url>
  </required_header>
  <id_info>
    <org_study_id>ChinaIMF</org_study_id>
    <nct_id>NCT02902432</nct_id>
  </id_info>
  <brief_title>A Trial of Endostar in Patients With Carcinoma of the Head and Neck</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>China International Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Society of Clinical Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China International Medical Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of recombinant human&#xD;
      endostatin（continuously-pumped）combined with chemoradiotherapy in patients with advanced&#xD;
      squamous cell carcinoma of the head and neck. The patients will be randomized to concurrent&#xD;
      radiotherapy (CRT) arm and CRT + Endostar arm. All patients will receive one cycles of&#xD;
      induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin&#xD;
      and 3 cycles of chemotherapy after IMRT. Treatment cycles will be repeated every 21 days for&#xD;
      a maximum of 4 cycles. In CRT + Endostar arm, Endostar will be continuously intravenous&#xD;
      pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week (d-5-d-1,&#xD;
      d3-d7, d10-d14, d17-d21) during IMRT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will be randomized to CRT arm and CRT + Endostar arm. All patients will receive&#xD;
      one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with&#xD;
      weekly cisplatin and 3 cycles of chemotherapy after IMRT. Treatment cycles will be repeated&#xD;
      every 21 days for a maximum of 4 cycles. In CRT + Endostar arm, Endostar will be continuously&#xD;
      intravenous pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week&#xD;
      (d-5-d-1, d3-d7, d10-d14, d17-d21) during IMRT.&#xD;
&#xD;
      Prior to enrollment in this study and while the patient is receiving the therapy, routine&#xD;
      tests, ECG, head and neck CT scan and MRI will be performed to check the body's response to&#xD;
      the treatment. Further more, before and after the treatment, the circulating endothelial&#xD;
      cells (CECs), endothelial progenitor cells (CEPs), vascular endothelial growth factor (VEGF),&#xD;
      Cancer embryo antigen (CEA), Neuron-specific enolase (NSE) in blood and Microvessel density&#xD;
      (MVD), hypoxia-inducible factor-1a (HIF-1a), P53, VEGF, Survivin in pathological specimens&#xD;
      will be tested.&#xD;
&#xD;
      Patients with progressive disease or intolerable side effects will be removed from the study.&#xD;
      Patients with stable disease or tumor response will continue therapy for a maximum of 4&#xD;
      cycles.&#xD;
&#xD;
      Primary outcome: The response rate (RR), the clinical benefit rate (CBR), time of tumor&#xD;
      progression (TTP).&#xD;
&#xD;
      Secondary outcomes: The quality of life (QOL)，Safety and Tolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (Mon); PFS, According to RECIST v1.1</measure>
    <time_frame>up to 40 months</time_frame>
    <description>Time of tumor progression in patients with head and neck squamous cell carcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL); Scores range from 0 to 5</measure>
    <time_frame>up to 40 months</time_frame>
    <description>Quality of life (QOL) in cancer patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>SCCHN</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients with advanced squamous cell carcinoma of the head and neck.IMRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCCHN-Endostar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with advanced squamous cell carcinoma of the head and neck.Endostar will be continuously intravenous pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week(d-5-d-1, d3-d7, d10-d14, d17-d21)during IMRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.</description>
    <arm_group_label>SCCHN</arm_group_label>
    <arm_group_label>SCCHN-Endostar</arm_group_label>
    <other_name>recombinant human endostatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed unrespectable or postoperative recurrent squamous cell&#xD;
             carcinoma of the head and neck;&#xD;
&#xD;
          -  No prior radiation or chemotherapy and biotherapy before;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.Life expectancy&#xD;
             greater than 3 months;&#xD;
&#xD;
          -  Patients must have adequate bone marrow function:&#xD;
&#xD;
               -  Platelets ≥ 80×109/L&#xD;
&#xD;
               -  Hemoglobin ≥100 g/L&#xD;
&#xD;
               -  Absolute NeutrophilCount ≥1.5×109/L&#xD;
&#xD;
               -  white blood cell≥ 3.5×109/L&#xD;
&#xD;
          -  Patients must have adequate liver and renal function:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) &lt; 2.5 × upper&#xD;
                  limit of normal&#xD;
&#xD;
               -  Alkaline phosphatase &lt; 2.5 × upper limit of normal&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
               -  Creatinine &lt;1.5 mg/dL× upper limit of normal&#xD;
&#xD;
          -  A cardiac ejection fraction &gt; 50%;&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any investigational drug study within 4 weeks preceding the start of&#xD;
             study treatment;&#xD;
&#xD;
          -  Age ≤18 or ≥75 years of Age;&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
&#xD;
          -  Serious, uncontrolled, concurrent infection(s) requiring antibiotics;&#xD;
&#xD;
          -  Clinically apparent central nervous system metastases or carcinomatous meningitis;&#xD;
&#xD;
          -  Treatment for other carcinomas within the last 3 months;&#xD;
&#xD;
          -  Patient unable or not willing to perform all study related biopsies and blood draws&#xD;
             for exploratory endpoints will not be enrolled on study as all study related&#xD;
             procedures are mandatory;&#xD;
&#xD;
          -  Patients with clinically significant cardiac disease (New York Heart Association&#xD;
             Classification III or IV and cardiac arrhythmias not well controlled with medication),&#xD;
             or myocardial infarction within the previous six months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ping liu, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the Second Xiangya Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China International Medical Foundation</investigator_affiliation>
    <investigator_full_name>Ping Liu</investigator_full_name>
    <investigator_title>Attending doctor in oncology</investigator_title>
  </responsible_party>
  <keyword>endostar</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostar protein</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

